Scholarlink

Background <p>Infertility is a growing concern, with metabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and polycystic ovarian syndrome (PCOS) being associated with it. Insulin resistance is seen to be the central feature of these conditions which ends up disrupting hormonal balance and also impairs fertility in both men and women. Hence, understanding the connection between new antidiabetic drugs and fertility can open new possibilities for fertility care.</p> Main body <p>This review studies the role of antidiabetic drugs in improving reproductive outcomes by targeting insulin resistance and related metabolic dysfunctions. Metformin which is the most widely used insulin sensitizer has evidence to improve ovulation in women with PCOS and is seen to be enhancing sperm count, motility and hormone levels in diabetic males by reducing oxidative stress and inflammation. GLP-1 (Glucagon-like peptide-1) receptor agonists include liraglutide and exenatide which support weight loss, improve insulin sensitivity and show positive effects on testosterone levels, ovulation and menstrual regularity. Current growing agents like SGLT2 <b>(</b>Sodium-glucose cotransporter-2<b>)</b> inhibitors and DPP-4 <b>(</b>Dipeptidyl Peptidase-4 inhibitors) inhibitors are also being studied for their potential reproductive too. During pregnancy, glycemic control is critical where metformin and insulin are relatively well-studied, newer agents show variable placental transfer and safety profiles. Further research is required to create new treatment protocols and guidelines to fully understand their long-term reproductive effects in both sexes.</p> Conclusion <p>Antidiabetic drugs that improve insulin sensitivity offer promising avenues for addressing infertility associated with metabolic disorders. However, gaps remain regarding their long-term preconceptional and postconceptional reproductive effects, underscoring the need for further targeted research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antidiabetic pharmacotherapy aiding in fertility restoration: an integrative review of current evidence

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月17日

查看全文
  • Rowyna Reji Koshy,
  • Arsha Anil Kumar,
  • Binu Thomas Maliyil,
  • Roslyne Regie,
  • Sarath Jairaj,
  • Megha Satish

摘要

Background

Infertility is a growing concern, with metabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and polycystic ovarian syndrome (PCOS) being associated with it. Insulin resistance is seen to be the central feature of these conditions which ends up disrupting hormonal balance and also impairs fertility in both men and women. Hence, understanding the connection between new antidiabetic drugs and fertility can open new possibilities for fertility care.

Main body

This review studies the role of antidiabetic drugs in improving reproductive outcomes by targeting insulin resistance and related metabolic dysfunctions. Metformin which is the most widely used insulin sensitizer has evidence to improve ovulation in women with PCOS and is seen to be enhancing sperm count, motility and hormone levels in diabetic males by reducing oxidative stress and inflammation. GLP-1 (Glucagon-like peptide-1) receptor agonists include liraglutide and exenatide which support weight loss, improve insulin sensitivity and show positive effects on testosterone levels, ovulation and menstrual regularity. Current growing agents like SGLT2 (Sodium-glucose cotransporter-2) inhibitors and DPP-4 (Dipeptidyl Peptidase-4 inhibitors) inhibitors are also being studied for their potential reproductive too. During pregnancy, glycemic control is critical where metformin and insulin are relatively well-studied, newer agents show variable placental transfer and safety profiles. Further research is required to create new treatment protocols and guidelines to fully understand their long-term reproductive effects in both sexes.

Conclusion

Antidiabetic drugs that improve insulin sensitivity offer promising avenues for addressing infertility associated with metabolic disorders. However, gaps remain regarding their long-term preconceptional and postconceptional reproductive effects, underscoring the need for further targeted research.